Development and External Evaluation of Hypoxia-Related Prognostic Signatures in Head and Neck Squamous Cell Carcinoma.
- 1School of Computer Sciences and Engineering, Bangor University, Bangor LL57 1UT, UK.
- 2Division of Cancer Sciences, University of Manchester, Manchester M20 4GJ, UK.
Abstract
Background
We evaluated breast cancer-derived hypoxia and radiosensitivity signatures in head and neck squamous cell carcinoma (HNSCC), then developed and externally evaluated HNSCC prognostic signatures from hypoxia-related genes.Methods
This retrospective study used TCGA HNSC for development (514 patients; 217 deaths) and GSE65858 for external evaluation (270 patients; 94 deaths). LASSO Cox regression selected models from 414 hypoxia-related genes measurable in both cohorts. The 32-gene primary model and 13-gene sensitivity model were locked before external survival testing. External analyses assessed continuous scores, with additional adjustment for age, stage, tumour site, HPV DNA status and smoking. Cross validation with standardisation within training folds and bootstrap gene selection stability were examined in subsequent checks.Results
The main analyses did not establish prognostic associations for the breast-derived signatures in HNSCC. The primary HNSCC model had a mean development cross-validation C index of 0.628. In GSE65858, univariable hazard ratios per score standard deviation were 1.29 (95% confidence interval 1.05 to 1.59; p = 0.016) for the primary model and 1.28 (1.03 to 1.59; p = 0.024) for the sensitivity model. Their C indices were 0.566 and 0.581. After clinical adjustment in 265 patients with 92 deaths, the corresponding hazard ratios were 1.24 (0.99 to 1.55; p = 0.065) and 1.20 (0.95 to 1.51; p = 0.117). Neither signature reached statistical significance in the analyses using detailed HPV information. Five-year median-split log-rank p values were 0.095 and 0.204.Conclusions
The signatures showed unadjusted associations with overall survival in an external cohort, but discrimination was modest and independent prognostic value was not established after clinical adjustment. These exploratory prognostic signatures require further evaluation alongside clinical factors. The findings do not establish a quantitative measure of tumour hypoxia or utility for treatment selection.
Related
- Morphologic intratumoral heterogeneity from routine whole-slide histopathology is prognostic for survival in primary central nervous system lymphoma: development in the LOC Network and international external validation
- Development and External Validation of an M2 Macrophage-Related Prognostic Signature in Breast Cancer Using Multi-Omics Data and Machine Learning.
- External Evaluation of Multi-Omics Prognostic Models Across TCGA-BRCA and METABRIC: Transportability, Stability, and Incremental Performance
- Salivary prognostic bacterial signatures associated with survival outcomes and recurrence risk in head and neck squamous cell carcinoma
- MELD-S prognostic model: development and external validation for 90-day mortality prediction in acute-on-chronic liver failure
BibTeX
@article{osei2026development,
title = {{Development and External Evaluation of Hypoxia-Related Prognostic Signatures in Head and Neck Squamous Cell Carcinoma.}},
author = {Jimmy Carter Osei and Abdullah Aziz and Tim Andrew Davies Smith},
journal = {Genes},
year = {2026},
month = oct,
doi = {10.3390/genes17101256},
url = {https://europepmc.org/article/MED/42938372},
note = {CC BY},
}
RIS
TY - JOUR
TI - Development and External Evaluation of Hypoxia-Related Prognostic Signatures in Head and Neck Squamous Cell Carcinoma.
AU - Jimmy Carter Osei
AU - Abdullah Aziz
AU - Tim Andrew Davies Smith
PY - 2026
DA - 2026/10/11
JO - Genes
DO - 10.3390/genes17101256
UR - https://europepmc.org/article/MED/42938372
AB - Background We evaluated breast cancer-derived hypoxia and radiosensitivity signatures in head and neck squamous cell carcinoma (HNSCC), then developed and externally evaluated HNSCC prognostic signatures from hypoxia-related genes.Methods This retrospective study used TCGA HNSC for development (514 patients; 217 deaths) and GSE65858 for external evaluation (270 patients; 94 deaths). LASSO Cox regression selected models from 414 hypoxia-related genes measurable in both cohorts. The 32-gene primary model and 13-gene sensitivity model were locked before external survival testing. External analyses assessed continuous scores, with additional adjustment for age, stage, tumour site, HPV DNA status and smoking. Cross validation with standardisation within training folds and bootstrap gene selection stability were examined in subsequent checks.Results The main analyses did not establish prognostic associations for the breast-derived signatures in HNSCC. The primary HNSCC model had a mean development cross-validation C index of 0.628. In GSE65858, univariable hazard ratios per score standard deviation were 1.29 (95% confidence interval 1.05 to 1.59; p = 0.016) for the primary model and 1.28 (1.03 to 1.59; p = 0.024) for the sensitivity model. Their C indices were 0.566 and 0.581. After clinical adjustment in 265 patients with 92 deaths, the corresponding hazard ratios were 1.24 (0.99 to 1.55; p = 0.065) and 1.20 (0.95 to 1.51; p = 0.117). Neither signature reached statistical significance in the analyses using detailed HPV information. Five-year median-split log-rank p values were 0.095 and 0.204.Conclusions The signatures showed unadjusted associations with overall survival in an external cohort, but discrimination was modest and independent prognostic value was not established after clinical adjustment. These exploratory prognostic signatures require further evaluation alongside clinical factors. The findings do not establish a quantitative measure of tumour hypoxia or utility for treatment selection.
SN - 2073-4425
ER -